Literature DB >> 30350882

Close correlation between hyperandrogenism and insulin resistance in women with polycystic ovary syndrome-Based on liquid chromatography with tandem mass spectrometry measurements.

Yabo Yang1,2, Miao Ding1,2, Na Di1,2, Ricardo Azziz3, Dongzi Yang1,2, Xiaomiao Zhao1,2.   

Abstract

BACKGROUND: To investigate the correlation between hyperandrogenism (HA) and insulin resistance (IR) in women with polycystic ovary syndrome (PCOS) by measuring serum total testosterone (TT) using a liquid chromatography and tandem mass spectrometry assay (LC-MS/MS).
METHODS: This cohort study included 332 patients with PCOS, 63 patients with IR and 276 with controls. TT levels were measured by LC-MS/MS and chemiluminescent immunoassay (CLIA); glucose and insulin levels were determined by an oral glucose tolerance test (OGTT).
RESULTS: Compared with CLIA, LC-MS/MS differentiated more cases with high TT levels among the non-PCOS subjects with IR In patients with PCOS, LC-MS/MS-based TT levels or a combination with the mFG score detected a significantly higher incidence of HA in subjects with IR identified by hyperinsulinemia (HIN), HOMA-IR or impaired fasting glucose (IFG) than in those without IR Conversely, the IR rates demonstrated by HIN, HOMA-IR, or IFG were remarkably higher in the LC-MS/MS-defined high TT subgroup than in the normal TT subgroup. However, the CLIA platform could not discern a difference in HA incidence between IR and non-IR subgroups or in IR rate between high and normal TT populations. ROC curves also proved that HIN, HOMA-IR, and IFG were positive contributors to HA as measured by LC-MS/MS
CONCLUSIONS: The correlation between HA and IR has always been underestimated, partly owing to the less accurate methods previously used to measure TT. HIN, HOMA-IR, and IFG are likely to contribute to the development of HA from a clinical perspective.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  chemiluminescent immunoassay; hyperandrogenism; insulin resistance; liquid chromatography with tandem mass spectrometry; polycystic ovary syndrome

Mesh:

Substances:

Year:  2018        PMID: 30350882      PMCID: PMC6818543          DOI: 10.1002/jcla.22699

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  15 in total

1.  Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Hector F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

2.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2008-01       Impact factor: 19.112

3.  Defining hyperandrogenaemia according to the free androgen index in Chinese women: a cross-sectional study.

Authors:  Zehong Zhou; Renmin Ni; Yu Hong; Yu Li; Yunhui Wang; Xiaomiao Zhao; Dongzi Yang
Journal:  Clin Endocrinol (Oxf)       Date:  2012-09       Impact factor: 3.478

4.  Defining hirsutism in Chinese women: a cross-sectional study.

Authors:  Xiaomiao Zhao; Renmin Ni; Lin Li; Yaqin Mo; Jia Huang; Meifeng Huang; Ricardo Azziz; Dongzi Yang
Journal:  Fertil Steril       Date:  2011-07-18       Impact factor: 7.329

5.  Determining the normal cut-off levels for hyperandrogenemia in Chinese women of reproductive age.

Authors:  Xiaomiao Zhao; Zehui He; Yaqin Mo; Xiaoli Chen; Yaxiao Chen; Dongzi Yang
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2010-12-15       Impact factor: 2.435

Review 6.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

Authors: 
Journal:  Hum Reprod       Date:  2004-01       Impact factor: 6.918

7.  Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp.

Authors:  Nigel K Stepto; Samantha Cassar; Anju E Joham; Samantha K Hutchison; Cheryce L Harrison; Rebecca F Goldstein; Helena J Teede
Journal:  Hum Reprod       Date:  2013-01-12       Impact factor: 6.918

Review 8.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.

Authors:  Neil F Goodman; Rhoda H Cobin; Walter Futterweit; Jennifer S Glueck; Richard S Legro; Enrico Carmina
Journal:  Endocr Pract       Date:  2015-12       Impact factor: 3.443

9.  Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.

Authors:  R S Legro; A R Kunselman; W C Dodson; A Dunaif
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

10.  Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria.

Authors:  Wael A Salameh; Mildred M Redor-Goldman; Nigel J Clarke; Ruchi Mathur; Ricardo Azziz; Richard E Reitz
Journal:  Fertil Steril       Date:  2014-02-15       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.